SG11202009009UA - Viral and non-viral nanoplasmid vectors with improved production - Google Patents

Viral and non-viral nanoplasmid vectors with improved production

Info

Publication number
SG11202009009UA
SG11202009009UA SG11202009009UA SG11202009009UA SG11202009009UA SG 11202009009U A SG11202009009U A SG 11202009009UA SG 11202009009U A SG11202009009U A SG 11202009009UA SG 11202009009U A SG11202009009U A SG 11202009009UA SG 11202009009U A SG11202009009U A SG 11202009009UA
Authority
SG
Singapore
Prior art keywords
viral
improved production
nanoplasmid vectors
nanoplasmid
vectors
Prior art date
Application number
SG11202009009UA
Other languages
English (en)
Inventor
James A Williams
Original Assignee
Nature Tech Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nature Tech Corporation filed Critical Nature Tech Corporation
Publication of SG11202009009UA publication Critical patent/SG11202009009UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material
    • C12N2740/15052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/101Plasmid DNA for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/24Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/55Vectors comprising a special origin of replication system from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11202009009UA 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production SG11202009009UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862645892P 2018-03-21 2018-03-21
PCT/US2019/023209 WO2019183248A1 (fr) 2018-03-21 2019-03-20 Vecteurs nanoplasmidiques viraux et non viraux à production améliorée

Publications (1)

Publication Number Publication Date
SG11202009009UA true SG11202009009UA (en) 2020-10-29

Family

ID=66001381

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009009UA SG11202009009UA (en) 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production

Country Status (13)

Country Link
US (1) US20210010021A1 (fr)
EP (2) EP4151735A1 (fr)
JP (1) JP2021518150A (fr)
KR (1) KR20210016330A (fr)
CN (1) CN112154208A (fr)
AU (1) AU2019240068A1 (fr)
CA (1) CA3093346A1 (fr)
DK (1) DK3768846T3 (fr)
ES (1) ES2950736T3 (fr)
FI (1) FI3768846T3 (fr)
LT (1) LT3768846T (fr)
SG (1) SG11202009009UA (fr)
WO (1) WO2019183248A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022549138A (ja) 2019-09-18 2022-11-24 インターガラクティック セラピューティクス インコーポレイテッド 合成dnaベクターおよびその使用法
WO2022104109A1 (fr) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Cellules tueuses naturelles génétiquement modifiées et procédés d'utilisation associés
IL309532A (en) 2021-06-25 2024-02-01 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
CA3228262A1 (fr) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Cellules t de recepteur d'antigene chimerique activant le lat et leurs methodes d'utilisation
CN114045305B (zh) * 2021-10-15 2023-03-24 深圳市深研生物科技有限公司 多转座子系统
WO2023114901A2 (fr) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Méthodes et compositions pour la production de virus adéno-associé
WO2023172514A1 (fr) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Agents thérapeutiques de cellules immunitaires modifiés ciblés sur her2 et leurs procédés d'utilisation
WO2024020320A2 (fr) * 2022-07-19 2024-01-25 Rampart Bioscience, Inc. Vecteurs d'adn non immunogènes circulaires non viraux
CN117305339B (zh) * 2023-11-30 2024-02-06 苏州左旋星生物科技有限公司 优化大肠杆菌基因编辑的载体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
CA2794446C (fr) * 2001-04-04 2015-09-08 Genencor International, Inc. Mecanismes d'action productifs et cataboliques non couples des cellules hotes
WO2003091433A1 (fr) * 2002-04-26 2003-11-06 National Institute Of Advanced Industrial Science And Technology Systeme d'expression pour molecule d'arn a tige-boucle ayant un effet d'arni
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
EP1781800B1 (fr) 2004-08-19 2013-06-19 Nature Technology Corp. Procede de fermentation de l'adn plasmidique
CA2577519A1 (fr) * 2004-08-23 2006-03-30 Nucleonics, Inc. Constructions d'expression de promoteurs d'arn polymerase iii multiples
TWI311152B (en) 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
EP2152889B1 (fr) 2007-05-29 2017-03-15 Nature Technology Corporation Vecteurs et méthodes pour immunisation génétique
WO2009021288A1 (fr) * 2007-08-14 2009-02-19 Commonwealth Scientific And Industrial Research Organisation Procédé perfectionné de silençage génique
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
EA037273B1 (ru) * 2011-12-07 2021-03-02 Икнос Сайенсиз С.А. Экспрессионная кассета
CA2883227A1 (fr) * 2012-08-29 2014-03-06 Nature Technology Corporation Plasmides d'adn dotes d'une expression amelioree
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
AU2016338565B2 (en) 2015-10-14 2021-11-18 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
CN113498439A (zh) * 2018-12-20 2021-10-12 波赛达治疗公司 纳米转座子组合物及使用方法

Also Published As

Publication number Publication date
ES2950736T3 (es) 2023-10-13
EP3768846A1 (fr) 2021-01-27
KR20210016330A (ko) 2021-02-15
AU2019240068A1 (en) 2020-10-01
EP3768846B1 (fr) 2023-06-21
CN112154208A (zh) 2020-12-29
DK3768846T3 (da) 2023-07-24
LT3768846T (lt) 2023-08-10
JP2021518150A (ja) 2021-08-02
FI3768846T3 (fi) 2023-06-30
WO2019183248A1 (fr) 2019-09-26
CA3093346A1 (fr) 2019-09-29
US20210010021A1 (en) 2021-01-14
EP4151735A1 (fr) 2023-03-22

Similar Documents

Publication Publication Date Title
SG11202009009UA (en) Viral and non-viral nanoplasmid vectors with improved production
IL290102A (en) Viral vectors of cell lysis and their uses
IL271993A (en) Viral vectors of cell lysis and their uses
LT3670655T (lt) Proteinazės, turinčios pagerintas savybes
EP3558393A4 (fr) Vecteurs viraux adéno-associés
IL253820A0 (en) Retrovirus and lentivirus vectors
IL282885A (en) AAV viral vectors and their uses
EP3436576A4 (fr) Lignée cellulaire pour la production de protéine recombinante et/ou d'un vecteur viral recombinant
IL282053A (en) Constructions of glut1-linked recombinant aav vectors, preparations and kits containing them and their use
GB201814590D0 (en) Viral vector production system
IL290258A (en) Transgenic Isfahan Viral Vector
GB201706945D0 (en) Self-inactivating viral vector
IL284188A (en) Adapted orthopoxvirus vectors
HK1253863A1 (zh) 含prrsv次要蛋白的重組病毒載體及其製造方法與用途
SG11202006457YA (en) Modified orthopoxvirus vectors
EP3723813A4 (fr) Édition génomique à médiation par crispr avec des vecteurs
GB2571415B (en) Improved tinting shampoos
ZA202108996B (en) Viral vector
IL287071A (en) h factor vectors and their uses
ZA202104244B (en) Recombinant viruses and the uses thereof
EP3624825A4 (fr) Virus oncolytique recombinant
PL3250234T3 (pl) Rekombinowany mdv1 i jego zastosowania
EP3597759A4 (fr) Vecteur viral de borna et son utilisation
EP3621982A4 (fr) Système de production de vecteurs viraux
EP3371312A4 (fr) Analyse de vecteur viral et vecteur